The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy.

The new study, published in JAMA Network Open, should help ease any concerns patients may have about regularly taking ADHD medications. 

The use of NSAIDS such as ibuprofen and naproxen might not have the desired effect patients are seeking when it comes to joint pain, according to new findings to be presented at RSNA 2022. 

The U.S. Food and Drug Administration (FDA) has approved 501(k) marketing clearance for the prescription mobile app Parky for monitoring Parkinson’s Disease.

Hyperpolarized MRI may help identify metabolism problems—which can be an early signal of a heart condition—in real time.

The clinical application of scatter correction software is limited by numerous factors, according to a new analysis.

A team of Mayo Clinic specialists led the analysis, sharing their findings in Nature Medicine.

Also worth a look: the ACR Data Science Institute’s AI Central, updated this week with detailed information on imaging AI products that have been cleared by the FDA.

When lung cancer is caught in its early stages, long-term survival rates can reach 80% and higher, according to a new large-scale, 20-year international study presented at this year's RSNA meeting.

VT storm is associated with a heightened risk of death or significant complications. Early catheter ablation, it seems, is the most effective treatment option for this potentially fatal condition.